Drugs for Neurofibromatosis, Type Ii (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 48)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Lapatinib |
Approved, Investigational |
Phase 2 |
|
231277-92-2, 388082-78-8 |
208908 |
Synonyms:
FMM
FMM|GW 572016|GW572016|Tykerb®|Tyverb®
GSK-572016
GW 572016
GW-2016
GW572016
GW-572016
GW572016F
GW-572016F
GW-572016X
LAP016
LAPATINIB
LAPATINIB DITOLUENESULFONATE MONOHYDRATE
|
Lapatinib ditosylate
LAPATINIB DITOSYLATE MONOHYDRATE
Lapatinib tosilate hydrate
N-(3-Chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amino)methyl) -2-furyl)-4-quinazolinamine
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulphonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
N-{3-CHLORO-4-[(3-FLUOROPHENYL)METHOXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURANYL]-4-QUINAZOLINAMINE
Tycerb
Tykerb
TYVERB
|
|
2 |
|
Axitinib |
Approved, Investigational |
Phase 2 |
|
319460-85-0 |
6450551 |
Synonyms:
AG 013736
AG 013736|AG-013736|AG013736|Inlyta®
AG013736
AG-013736
AG-13736
|
AXITINIB
AXITINIBUM
INLYTA
N-METHYL-2-({3-[(E)-2-(PYRIDIN-2-YL)VINYL]-1H-INDAZOL-6-YL}SULFANYL)BENZAMIDE
N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
|
|
3 |
|
Lactitol |
Approved, Investigational |
Phase 2 |
|
585-86-4 |
157355 |
Synonyms:
4-O-beta-D-Galactopyranosyl-D-glucitol
4-O-β-D-Galactopyranosyl-D-glucitol
D-Lactitol
Emportal
Importal
Lactitol
|
Lactitolum
Neda lactiv importal
Oponaf
Pizensy
WURCS=2.0/2,2,1/[H2122H][a2112h-1b_1-5]/1-2/a4-b1
|
|
4 |
|
Acetylsalicylic acid |
Approved, Vet_approved |
Phase 2 |
|
50-78-2 |
2244 |
Synonyms:
2-(ACETYLOXY)BENZOATE
2-(ACETYLOXY)benzoIC ACID
2-Acetoxybenzenecarboxylate
2-ACETOXYBENZENECARBOXYLIC ACID
2-ACETOXYBENZOATE
2-ACETOXYBENZOIC ACID
2-CARBOXYPHENYL ACETATE
8-HOUR BAYER
A.S.A.
A.S.A. Empirin
ACARD
ACENTERINE
Acesal
Acetal
ACETARD
ACETICYL
Acetilsalicilico
Acetilum acidulatum
Acetisal
ACETOL
ACETONYL
ACETOPHEN
Acetophen®|acetylsalicylic acid|Aspirin®
ACETOSAL
ACETOSALIC ACID
ACETOSALIN
Acetoxybenzoic acid
ACETYLIN
Acetylsal
ACETYLSALIC ACID
ACETYLSALICYLATE
ACETYLSALICYLIC ACID
Acetylsalicylsaeure
Acetylsalicylsaure
ACETYLSALICYLSÄURE
ACETYONYL
ACETYSAL
ACETYSALICYLIC ACID
Acid, acetylsalicylic
Acide 2-(acetyloxy)benzoique
ACIDE 2-(ACÉTYLOXY)BENZOÏQUE
Acide acetylsalicylique
ACIDE ACÉTYLSALICYLIQUE
Acido acetilsalicilico
ÁCIDO ACETILSALICÍLICO
Acido O-acetil-benzoico
ACIDUM ACETYLSALICYLICUM
Acimetten
Acisal
ACYLPYRIN
Adiro
ALKA RAPID
Aloxiprimum
ANADIN ALL NIGHT
ANGETTES 75
ASA
Asagran
ASATARD
Ascoden-30
Aspalon
Aspec
ASPERGUM
ASPIRDROPS
ASPIRIN
Aspirina
Aspirine
Aspro
ASPRO CLR
Asteric
Azetylsalizylsaeure
AZETYLSALIZYLSÄURE
BAY1019036
BAYER EXTRA STRENGTH
Bayer Extra Strength Aspirin For Migraine Pain
BENASPIR
Bialpirina
BIALPIRINIA
Bi-prin
BUFFERIN
CAPRIN
CARDIOASPIRINA
Cemirit
Claradin
Clariprin
Colfarit
Contrheuma retard
Coricidin
Crystar
DANAMEP
Decaten
Delgesic
Dispril
DISPRIN CV
|
DISPRIN DIRECT
Dolean pH 8
Duramax
DURLAZA
EASPRIN
ECM
ECOLEN
ECOTRIN
EMPIRIN
ENDOSPRIN
ENDYDOL
ENPRIN
Entericin
Enterophen
Enterosarein
Enterosarine
Entrophen
EQUI-PRIN
Extren
GENCARDIA
Globentyl
Globoid
Helicon
Idragin
Kyselina 2-acetoxybenzoova
Kyselina acetylsalicylova
LEVIUS
Magnecyl
MAX STRGH ASPRO CLR
MEASURIN
Micristin
MICROPIRIN EC
Neuronika
Novid
NSC-27223
NSC-406186
Nu-seals
NU-SEALS 300
NU-SEALS 600
NU-SEALS 75
Nu-seals aspirin
NU-SEALS CARDIO 75
O-(ACETYLOXY)BENZOATE
O-(ACETYLOXY)BENZOIC ACID
O-accetylsalicylic acid
O-ACETOXYBENZOATE
O-ACETOXYBENZOIC ACID
O-Acetylsalicylate
O-ACETYLSALICYLIC ACID
O-CARBOXYPHENYL ACETATE
O-Carboxyphenyl acetic acid
PAYNOCIL
PERSISTIN
PHARMACIN
Pirseal
PLATET
PLATET 300
Polopirin
POLOPIRYNA
POSTMI 300
POSTMI 75
PREMASPIN
RHEUMINTABLETTEN
RHODINE
Rhonal
Salacetin
SALCETOGEN
SALETIN
Salicylate acetate
SALICYLIC ACID ACETATE
Salicylic acid acetic acid
Salicylic acid, acetate
SALOSPIR
Solfrin
SOLPRIN
SOLPRIN ACID
SOLPYRON
Solupsan
Spira-Dine
St. Joseph
St. Joseph Aspirin for Adults
Supac
TASPRIN
TEMPERAL
TOLDEX
TRIAMINICIN
Triple-sal
Vanquish
VAZALORE
Xaxa
Yasta
Zorprin
|
|
5 |
|
Lidocaine |
Approved, Vet_approved |
Phase 1, Phase 2 |
|
137-58-6 |
3676 |
Synonyms:
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-2ETN-2MePhAcN
a-Diethylamino-2,6-dimethylacetanilide
ALGRX 3268
ALGRX-3268
ALPHACAINE
alpha-Diethylamino-2,6-dimethylacetanilide
ANESTACON
Astrazeneca brand OF lidocaine
Dalcaine
Dentipatch
Dilocaine
EMBOLEX
IONTOCAINE
Jenapharm brand OF lidocanine hydrochloride
L-Caine
Lidocaina
Lidocaína
LIDOCAINE
Lidocaine carbonate
Lidocaine carbonate (2:1)
Lidocaine hydrocarbonate
Lidocaine hydrochloride
Lidocaine monoacetate
Lidocaine monohydrochloride
|
Lidocaine monohydrochloride, monohydrate
Lidocaine sulfate (1:1)
Lidocainum
LIDOCATON
Lidoderm
LIDOPEN
Lignocaine
LIGNOCAINE HCL
LIGNOSTAB
LMX 4
Novocol brand OF lidocaine hydrochloride
NSC-40030
Octocaine
ORAQIX
Strathmann brand OF lidocaine hydrochloride
VAGISIL
Xylesthesin
Xylocaine
Xylocaine®
Xylocitin
XYLODASE
Xyloneural
XYLOTOX
ZTLIDO
Α-diethylamino-2,6-dimethylacetanilide
|
|
6 |
|
Doxycycline |
Approved, Investigational, Vet_approved |
Phase 1, Phase 2 |
|
564-25-0 |
54671203 |
Synonyms:
(4S,4AR,5S,5ar,6R,12as)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
5-Hydroxy-a-6-deoxytetracycline
5-Hydroxy-alpha-6-deoxytetracycline
5-Hydroxy-α-6-deoxytetracycline
6a-Deoxy-5-oxytetracycline
6-alpha-deoxy-5-oxytetracycline
6alpha-Deoxy-5-oxytetracycline
6Α-deoxy-5-oxytetracycline
Anhydrous doxycycline
BMY-28689|Monodox®|Vibramycin®
Doxcycline anhydrous
Doxiciclina
DOXY
Doxychel
Doxycyclin
Doxycycline
|
Doxycycline (anhydrous)
DOXYCYCLINE ANHYDROUS
DOXYCYCLINE HCL
Doxycycline hyclate
Doxycycline hydrate
Doxycycline hydric acid
Doxycycline monohydrate
Doxycycline monohydric acid
Doxycyclinum
Doxytetracycline
GS-3065
Jenacyclin
Monodox
Oracea
Supracyclin
Vibramycin
|
|
7 |
|
Crizotinib |
Approved, Investigational |
Phase 2 |
|
877399-52-5 |
11626560 |
Synonyms:
(<i>R</i>)-crizotinib|PF 2341066|PF-02341066|PF-2341066|PF2341066|Xalkori®
(R)-CRIZOTINIB
CRIZOTINIB
Crizotinibum
PF 2341066
|
PF-02341066
PF2341066
PF-2341066
XALKORI
|
|
8 |
|
Everolimus |
Approved |
Phase 2 |
|
159351-69-6 |
70789204 6442177 |
Synonyms:
001, RAD
40-O-(2-Hydroxyethyl)-rapamycin
42-O-(2-HYDROXYETHYL)RAPAMYCIN
Afinitor
AFINITOR DISPERZ
Afinitor®|Certican®|RAD-001|RAD001|rapamycin, 42-O-(2-hydroxyethyl)-|Zortress®
Certican
EVEROLIMUS
évérolimus
RAD 001
|
RAD 666
RAD, SDZ
RAD001
RAD-001
RAD-666
SDZ RAD
SDZ-RAD
VOTUBIA
ZORTRESS
|
|
9 |
|
Endostatins |
|
Phase 2 |
|
|
|
10 |
|
Analgesics |
|
Phase 2 |
|
|
|
11 |
|
Antirheumatic Agents |
|
Phase 2 |
|
|
|
12 |
|
Fibrinolytic Agents |
|
Phase 2 |
|
|
|
13 |
|
Antipyretics |
|
Phase 2 |
|
|
|
14 |
|
Cyclooxygenase Inhibitors |
|
Phase 2 |
|
|
|
15 |
|
Platelet Aggregation Inhibitors |
|
Phase 2 |
|
|
|
16 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 2 |
|
|
|
17 |
|
Analgesics, Non-Narcotic |
|
Phase 2 |
|
|
|
18 |
|
Anti-Inflammatory Agents |
|
Phase 2 |
|
|
|
19 |
|
Antiprotozoal Agents |
|
Phase 1, Phase 2 |
|
|
|
20 |
|
Antiparasitic Agents |
|
Phase 1, Phase 2 |
|
|
|
21 |
|
Antimalarials |
|
Phase 1, Phase 2 |
|
|
|
22 |
|
Protein Kinase Inhibitors |
|
Phase 2 |
|
|
|
23 |
|
Immunosuppressive Agents |
|
Phase 2 |
|
|
|
24 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
25 |
|
Sirolimus |
Approved, Investigational |
Phase 1 |
|
53123-88-9 |
5284616 6436030 |
Synonyms:
(-)-Rapamycin
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
Antibiotic ay 22989
AY-22989
AY-22989|Fyarro® (sirolimus albumin-bound particles)|Rapamune®|rapamycin|WY-090217
L04AA10
NSC-226080
Perceiva
RAPA
Rapammune
|
Rapamune
Rapamycin
Rapamysin
RPM
Sirolimus
Sirolimús
Sirolimusum
SM-88 COMPONENT SIROLIMUS
WY-090217
|
|
26 |
|
Bevacizumab |
Approved, Investigational |
Phase 1 |
|
216974-75-3 |
135329020 |
Synonyms:
12-IGG1
ANTIVEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF monoclonal antibody
AVA-1
AVASTIN
Bevacizumab
BEVACIZUMAB BETA
bevacizumab-awwb
|
BI 695502
BS-503A
FKB-238
HLX04
HLX-04
R-435
RG-435
RHUMAB-
rhuMAb-VEGF
|
|
27 |
|
Cetuximab |
Approved |
Phase 1 |
|
205923-56-4 |
|
Synonyms:
ABP-494
ANTI EGFR
C225
C-225
C225|Erbitux®|IMC-225|IMC-C225
CETUXIMAB
Cétuximab
CETUXIMAB (GENETICAL RECOMBINATION)
|
Cetuximabum
CMAB009
CMAB-009
ERBITUX
IMC-225
IMC-C225
MOAB C225
|
|
28 |
|
Valproic acid |
Approved, Investigational |
Phase 1 |
|
99-66-1 |
3121 |
Synonyms:
(N-C3H7)2chcooh
(S)-2-Propyl-4-pentanoate
(S)-2-Propyl-4-pentanoic acid
2 Propylpentanoic acid
2-N-PROPYL-4-PENTENOIC ACID
2-N-Propyl-N-valerate
2-N-Propyl-N-valeric acid
2-Propylpentanoate
2-PROPYL-pentanoate
2-Propylpentanoic acid
2-PROPYL-pentanoIC ACID
2-Propylvalerate
2-Propylvaleric acid
44089
4-Heptanecarboxylate
4-Heptanecarboxylic acid
A-44090
A-44090|Depakote®|Epilim®|valproate sodium
Acetate, dipropyl
Acid, propylisopropylacetic
Acid, valproic
Acide valproique
acide valproïque
Acido valproico
ácido valproico
Acidum valproicum
Alti-valproic
Apo-divalproex
Apo-valproic
Apo-valproic syrup
Avugane
Baceca
Calcium valproate
Calcium, valproate
Convulex
Convulsofin
Delepsine
Depacon
Depakene
Depakin
Depakin chrono
Depakine
Depakine chrono
Depakote
Deproic
Di-N-propylacetate
Di-N-propylacetic acid
Di-N-propylessigsaeure
Di-N-propylessigsaure
Di-n-propylessigsäure
Dipropyl acetate
Dipropylacetate
Dipropylacetic acid
Divalproex
Divalproex sodium
DOM-divalproex
Dom-valproate
DOM-valproic
Dom-valproic acid
DOM-valproic acid e.c.
Dom-valproic acid syrup
DPA
Epiject i.v.
Epilex
Epilim
|
Epival
Epival er
Ergenyl
Gen-divalproex
Kyselina 2-propylvalerova
LEP321
Magnesium valproate
Med valproic
Mylproin
Myproate
Myproic acid
N-Dipropylacetic acid
N-DPA
Novo-divalproex
Novo-valproic
Novo-valproic - ecc
Novo-valproic soft gel cap
NSC-93819
Nu-valproic
PEAC
Penta-valproic
PHL-Valproate
PHL-Valproic acid
PHL-Valproic acid e.c.
PMS-Divalproex
PMS-Valproate
PMS-Valproic acid
PMS-Valproic acid e.c.
Propylisopropylacetic acid
Propylvaleric acid
Ratio-valproic - ecc
S(-)-4-En-valproate
S(-)-4-En-valproic acid
S-2-N-Propyl-4-pentenoate
S-2-N-Propyl-4-pentenoic acid
Sandoz valproic
Savicol
Semisodium valproate
Sodium hydrogen divalproate
Sodium valproate
Sodium, divalproex
Sodium, valproate
Sprinkle
STAVZOR
Valcote
Valparin
Valproate
Valproate calcium
Valproate semisodique [French]
Valproate semisodium
Valproate sodium
Valproate, calcium
Valproate, magnesium
Valproate, semisodium
Valproate, sodium
Valproato semisodico [Spanish]
Valproatum seminatricum [Latin]
VALPROIC ACID
Valproic acid usp
Valproic acid USP24
Valproic acid, sodium salt (2:1)
Valproinsaeure
Valproinsäure
VPA
Vupral
|
|
29 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 1 |
|
22916-47-8 |
4189 |
Synonyms:
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
Brentan
CONOFITE
Dactarin
DERMAZOLE
DUMICOAT
Esteve brand OF miconazole
florid(nitrate)|Monistat®|R-14889
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
LORAMYC
MCZ
MICATIN
|
Miconasil nitrate
Miconazol
Miconazole
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazolum
Monistat
MONISTAT-3
MONISTAT-DERM
Nitrate, miconasil
Nitrate, miconazole
NSC-170986
Oravig
VUSION
|
|
30 |
|
Clotrimazole |
Approved, Vet_approved |
Phase 1 |
|
23593-75-1 |
2812 |
Synonyms:
(Chlorotrityl)imidazole
1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole
1-(a-(2-Chlorophenyl)benzhydryl)imidazole
1-(alpha-(2-Chlorophenyl)benzhydryl)imidazole
1-(O-Chloro-a,a-diphenylbenzyl)imidazole
1-(O-Chloro-alpha,alpha-diphenylbenzyl)imidazole
1-(O-Chlorotrityl)imidazole
1-(O-Chloro-α,α-diphenylbenzyl)imidazole
1-(Α-(2-chlorophenyl)benzhydryl)imidazole
ABTRIM
ACTAVALL
Bay b 5097
BAY-5097
Bayer brand 1 OF clotrimazole
Bayer brand 2 OF clotrimazole
CANDIDEN
Canesten
Canesten 1-day cream combi-pak
Canesten 1-day therapy
Canesten 3-day therapy
Canesten 6-day therapy
CANESTEN AF
Canesten combi-pak 1-day therapy
Canesten combi-pak 3-day therapy
Canesten cream
CANESTEN CRM COMBI
CANESTEN INTERNAL
Canesten solution
CANESTEN VC
Canesten®|Lotrimin®
Canestine
Chlotrimazole
Clotrimaderm
Clotrimaderm cream
Clotrimazol
CLOTRIMAZOLE
Clotrimazole schering brand
Clotrimazolum
Desamix F
Empecid
FB b 5097
Fem care
FemCare
FUNGEDERM
GNF-PF-3499
Gyne lotrimin
Gyne-lotrimin
Gyne-lotrimin 3
Gyne-lotrimin 3 combination pack
Gyne-lotrimin combination pack
Gyne-lotrimin3
Gyne-lotrimin3 combination pack
|
Gynix
Kanesten
Klotrimazole
Lopac-C-6019
Lotrimax
Lotrimin
LOTRIMIN (TN)
Lotrimin af
Lotrimin af cream
Lotrimin af jock-itch cream
Lotrimin af lotion
Lotrimin af solution
Lotrimin cream
Lotrimin lotion
Lotrimin solution
Lotrisone
MASNODERM
mono-Baycuten
Monobaycuten
Mycelax
Mycelex
MYCELEX (TN)
Mycelex 7
Mycelex cream
Mycelex g
Mycelex otc
Mycelex solution
Mycelex troches
Mycelex twin pack
Mycelex: mycosporinrimazole
Mycelex-7
Mycelex-7 combination pack
Mycelex-g
MYCIL GOLD
Myclo cream
Myclo solution
Myclo spray solution
Myclo-gyne
Mycosporin
Mykosporin
Neo-zol cream
NSC-257473
Otomax
Pedisafe
Prestwick_120
PRIVACOM
Rimazole
Schering brand OF clotrimazole
Tibatin
Trimysten
Trivagizole 3
Veltrim
|
|
31 |
|
Angiogenesis Inhibitors |
|
Phase 1 |
|
|
|
32 |
|
Anti-Bacterial Agents |
|
Phase 1 |
|
|
|
33 |
|
Anti-Infective Agents |
|
Phase 1 |
|
|
|
34 |
|
Immunoglobulins, Intravenous |
|
Phase 1 |
|
|
|
35 |
|
Immunoglobulins |
|
Phase 1 |
|
|
|
36 |
|
Antibodies, Monoclonal |
|
Phase 1 |
|
|
|
37 |
|
Antibodies |
|
Phase 1 |
|
|
|
38 |
|
Antineoplastic Agents, Immunological |
|
Phase 1 |
|
|
|
39 |
|
Endothelial Growth Factors |
|
Phase 1 |
|
|
|
40 |
|
Mitogens |
|
Phase 1 |
|
|
|
41 |
|
Neurotransmitter Agents |
|
Phase 1 |
|
|
|
42 |
|
Immunoglobulin G |
|
Phase 1 |
|
|
|
43 |
|
Antifungal Agents |
|
Phase 1 |
|
|
|
44 |
|
Psychotropic Drugs |
|
Phase 1 |
|
|
|
45 |
|
Anticonvulsants |
|
Phase 1 |
|
|
|
46 |
|
Antibiotics, Antitubercular |
|
Phase 1 |
|
|
|
47 |
|
Dermatologic Agents |
|
|
|
|
|
48 |
|
Histone Deacetylase Inhibitors |
|
Early Phase 1 |
|
|
|
Interventional clinical trials:
(show all 44)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Parallel-group, Two-staged, Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants With Progressive NF2 Mutated Meningiomas |
Recruiting |
NCT05130866 |
Phase 2, Phase 3 |
REC-2282;Placebo |
2 |
Phase II Study of Lapatinib in Children and Adults With Neurofibromatosis Type 2(NF2) and NF2-related Tumors |
Completed |
NCT00973739 |
Phase 2 |
Lapatinib |
3 |
Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 |
Completed |
NCT00004437 |
Phase 2 |
|
4 |
A Single Arm, Single Center, Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma |
Completed |
NCT01490476 |
Phase 2 |
RAD001 |
5 |
A Single Arm Phase 2 Study of the Dual mTORC1/mTORC2 Inhibitor AZD2014 Provided on an Intermittent Schedule for Neurofibromatosis 2 Patients With Progressive or Symptomatic Meningiomas |
Completed |
NCT02831257 |
Phase 2 |
AZD2014 |
6 |
Recombinant Human Endostatin Injection Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors by Continuous Intravenous Pumping |
Completed |
NCT02104323 |
Phase 2 |
Endostatin |
7 |
Phase II Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas |
Completed |
NCT02129647 |
Phase 2 |
Axitinib |
8 |
Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas |
Completed |
NCT01125046 |
Phase 2 |
|
9 |
Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 |
Completed |
NCT01419639 |
Phase 2 |
Everolimus (RAD001) , Afinitor® |
10 |
Phase 2 Study of Bevacizumab in Children and Adults With Neurofibromatosis Type 2 and Symptomatic Vestibular Schwannoma |
Completed |
NCT01207687 |
Phase 2 |
|
11 |
Open-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or Radiation |
Completed |
NCT01767792 |
Phase 2 |
Bevacizumab |
12 |
Icotinib Hydrochloride Tablets Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors |
Completed |
NCT02934256 |
Phase 2 |
Icotinib |
13 |
Prospective, Randomized, Placebo-Controlled Phase II Trial of Aspirin for Vestibular Schwannomas |
Recruiting |
NCT03079999 |
Phase 2 |
Aspirin;Placebo |
14 |
Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors |
Recruiting |
NCT03095248 |
Phase 2 |
Selumetinib |
15 |
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) |
Recruiting |
NCT04374305 |
Phase 2 |
Brigatinib;Neratinib |
16 |
Doxycycline Injection of Cutaneous Schwannoma in Neurofibromatosis Type 2 |
Recruiting |
NCT05521048 |
Phase 1, Phase 2 |
Doxycycline Injection [Doxy] |
17 |
Open-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas |
Active, not recruiting |
NCT04283669 |
Phase 2 |
Crizotinib |
18 |
A Single Arm, Monocenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma |
Active, not recruiting |
NCT01345136 |
Phase 2 |
RAD001, everolimus |
19 |
A Phase 2 Study to Assess the Efficacy, Safety, and Pharmacodynamic Activity of PTC299 in Patients With Neurofibromatosis Type 2 |
Terminated |
NCT00911248 |
Phase 2 |
PTC299 |
20 |
A Feasibility Study of the Placement, Use, and Safety of the Nucleus 24 Auditory Brainstem Implant in Non-Neurofibromatosis Type 2 (NF2) Pediatric Patients |
Unknown status |
NCT02102256 |
Phase 1 |
|
21 |
Penetrating Auditory Brainstem Implant for Neurofibromatosis 2 |
Completed |
NCT00030043 |
Phase 1 |
|
22 |
A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications |
Active, not recruiting |
NCT01552434 |
Phase 1 |
Temsirolimus;Valproic Acid |
23 |
A Feasibility Study of the Placement, Use, and Safety of the Nucleus 24 Auditory Brainstem Implant in Non-Neurofibromatosis Type 2 (NF2) Pediatric Patients |
Withdrawn |
NCT01850225 |
Phase 1 |
|
24 |
NF2 Natural History Consortium |
Unknown status |
NCT00004483 |
|
|
25 |
Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype |
Completed |
NCT02298270 |
|
|
26 |
Exploration and Estimation of Intratumoral Concentration and Activity of Lapatinib in Vivo in Vestibular Schwannomas |
Completed |
NCT00863122 |
Early Phase 1 |
lapatinib |
27 |
A Study Investigating the Inter- and Intra- Rater Reliability of Functional Outcome Measures in Neurofibromatosis 2 |
Completed |
NCT03617276 |
|
|
28 |
Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype |
Completed |
NCT02811718 |
|
|
29 |
Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas |
Completed |
NCT01880749 |
Early Phase 1 |
RAD001 |
30 |
The Effect of Changes in Head Position on Magnetic Resonance Image Distortion in Patients With Auditory Implants |
Completed |
NCT02246231 |
|
|
31 |
Whole Exome Sequencing (WES) of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data |
Completed |
NCT03210285 |
|
|
32 |
Using Positron Emission Tomography (PET) to Predict Intracranial Tumor Growth in Neurofibromatosis Type II (NF2) Patients |
Completed |
NCT01222728 |
|
|
33 |
Relationship Between Psychosocial Factors, Health Literacy, Quality of Life and Satisfaction With Medical Visits in Adults With Neurofibromatosis 1, Neurofibromatosis 2, and Schwannomatosis |
Completed |
NCT02435628 |
|
|
34 |
An Early Feasibility Study of the Safety and Efficacy of the Nucleus 24 Auditory Brainstem Implant in Children With Cochlear or Cochlear Nerve Disorders Not Resulting From Neurofibromatosis Type II |
Completed |
NCT01904448 |
|
|
35 |
Multicentre Prospective Observational Study: Resentment of Mucocutaneous Manifestations and the Value of Dermatological Examination in the Early Detection of Type 2 Neurofibromatosis in Children Under 15 Years of Age |
Recruiting |
NCT03893643 |
|
|
36 |
Neurofibromatosis (NF) Registry Portal Funded by Children's Tumor Foundation |
Recruiting |
NCT01885767 |
|
|
37 |
Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing |
Recruiting |
NCT03406208 |
|
|
38 |
Familial Investigations of Childhood Cancer Predisposition |
Recruiting |
NCT03050268 |
|
|
39 |
A Prospective Natural History Study of Patients With Neurofibromatosis Type 2 (NF2). |
Recruiting |
NCT00598351 |
|
|
40 |
Vestibular Precision: Physiology & Pathophysiology |
Enrolling by invitation |
NCT04890132 |
|
|
41 |
Compassionate Use Arm - ABI541 Auditory Brainstem Implant for Neurofibromatosis Type 2 Patients With Deafness |
No longer available |
NCT02589912 |
|
|
42 |
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma |
Terminated |
NCT02282917 |
Early Phase 1 |
AR-42 |
43 |
Study of the Nucleus 24 and ABI541 Auditory Brainstem Implants in Pediatric Non-Neurofibromatosis Type 2 |
Terminated |
NCT01864291 |
|
|
44 |
Study of Nucleus 24 and ABI541 Auditory Brainstem Implants (ABI) in Adult Non-Neurofibromatosis Type 2 Subjects |
Terminated |
NCT01736267 |
|
|
Cell-based therapeutics:
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Neurofibromatosis, Type Ii:
Embryonic/Adult Cultured Cells Related to Neurofibromatosis, Type Ii:
|